Monday, November 9, 2020

Pfizer & BioNTech's COVID-19 Vaccine Candidate Shows Efficacy Rate Above 90% In Interim Analysis

Pfizer Inc. (PFE) and BioNTech SE (BNTX) said the first set of results from the phase 3 COVID-19 vaccine trial provides initial evidence of the vaccine's ability to prevent COVID-19. Following the news, shares of Pfizer were trading up more than 11 percent in pre-market.

from RTT - Biotech https://ift.tt/2UbhGeu
via IFTTT

No comments:

Post a Comment